<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman's syndrome</z:e>, a <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disorder</z:e> involving a defect in the DNA coding for subunits of the <z:chebi fb="0" ids="16865">gamma-aminobutyric acid</z:chebi> (<z:chebi fb="3" ids="16865">GABA</z:chebi>) type A receptor, often is associated with <z:e sem="disease" ids="C1096063" disease_type="Disease or Syndrome" abbrv="">intractable epilepsy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Topiramate is a novel <z:chebi fb="0" ids="35623">anticonvulsant</z:chebi> that enhances GABAergic neurotransmission </plain></SENT>
<SENT sid="2" pm="."><plain>Five children with <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman's syndrome</z:e> and <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> were treated with topiramate for clinical indications </plain></SENT>
<SENT sid="3" pm="."><plain>The drug was effective and well tolerated, possibly because of its GABAergic properties </plain></SENT>
<SENT sid="4" pm="."><plain>Further studies are necessary to confirm and elucidate this observation </plain></SENT>
</text></document>